Publications by authors named "Yusuke Ogitani"

Claim this Profile
T
Tumour-resident oncolytic bacteria trigger potent anticancer effects through selective intratumoural thrombosis and necrosis.
Seigo Iwata, Taisei Nishiyama, Matomo Sakari, Yuki Doi, Naoki Takaya, Yusuke Ogitani

Nat Biomed Eng· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2.
Serena Lucotti, Yusuke Ogitani, Candia M Kenific, Jacob Geri, Young Hun Kim

Cell· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy.
Shigehiro Yagishita, Tadaaki Nishikawa, Hiroshi Yoshida, Daisuke Shintani, Sho Sato, Yusuke Ogitani

Clin Cancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.
Mikiko Suzuki, Shigehiro Yagishita, Kiyoshi Sugihara, Yusuke Ogitani, Tadaaki Nishikawa

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice.
Hiromi Okamoto, Masataka Oitate, Katsunobu Hagihara, Hideyuki Shiozawa, Yoshitake Furuta, Yusuke Ogitani

Xenobiotica· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers.
Ayuko Hoshino, Han Sang Kim, Linda Bojmar, Kofi Ennu Gyan, Michele Cioffi, Yusuke Ogitani

Cell· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Yuuri Hashimoto, Kumiko Koyama, Yasuki Kamai, Kenji Hirotani, Yusuke Ogitani

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Tomomi Nakayama Iwata, Chiaki Ishii, Saori Ishida, Yusuke Ogitani, Teiji Wada

Mol Cancer Ther· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Toshihiko Doi, Kohei Shitara, Yoichi Naito, Akihiko Shimomura, Yasuhiro Fujiwara, Yusuke Ogitani

Lancet Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Naoki Takegawa, Yoshikane Nonagase, Kimio Yonesaka, Kazuko Sakai, Osamu Maenishi, Yusuke Ogitani

Int J Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi, Chiaki Ishii

Clin Cancer Res· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology.
Yusuke Ogitani, Yuki Abe, Takuma Iguchi, Junko Yamaguchi, Tomoko Terauchi

Bioorg Med Chem Lett· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate, Hiroyuki Naito, Toshinori Agatsuma

Cancer Sci· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads.
Takashi Nakada, Takeshi Masuda, Hiroyuki Naito, Masao Yoshida, Shinji Ashida, Yusuke Ogitani

Bioorg Med Chem Lett· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calcitonin gene-related peptide regulates type IV hypersensitivity through dendritic cell functions.
Norihisa Mikami, Kaori Sueda, Yusuke Ogitani, Ippei Otani, Miku Takatsuji

PLoS One· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Calcitonin gene-related peptide is an important regulator of cutaneous immunity: effect on dendritic cell and T cell functions.
Norihisa Mikami, Hiroaki Matsushita, Tetsuya Kato, Rumi Kawasaki, Taichi Sawazaki, Yusuke Ogitani

J Immunol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice.
Kazutake Tsujikawa, Katsutoshi Yayama, Tamon Hayashi, Hiroaki Matsushita, Taijiro Yamaguchi, Yusuke Ogitani

Proc Natl Acad Sci U S A· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis